IN2014MN01839A - - Google Patents

Info

Publication number
IN2014MN01839A
IN2014MN01839A IN1839MUN2014A IN2014MN01839A IN 2014MN01839 A IN2014MN01839 A IN 2014MN01839A IN 1839MUN2014 A IN1839MUN2014 A IN 1839MUN2014A IN 2014MN01839 A IN2014MN01839 A IN 2014MN01839A
Authority
IN
India
Prior art keywords
compounds
formula
relates
oxides
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjay Kumar
Rajiv Sharma
Vishal Ashok Mahajan
Sangameshwar Prabhakar Sawargave
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of IN2014MN01839A publication Critical patent/IN2014MN01839A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D307/08Preparation of tetrahydrofuran
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1839MUN2014 2012-02-28 2013-02-27 IN2014MN01839A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603988P 2012-02-28 2012-02-28
US201261736622P 2012-12-13 2012-12-13
PCT/IB2013/051555 WO2013128378A1 (en) 2012-02-28 2013-02-27 Phenyl alkanoic acid derivatives as gpr agonists

Publications (1)

Publication Number Publication Date
IN2014MN01839A true IN2014MN01839A (de) 2015-07-03

Family

ID=48225087

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1839MUN2014 IN2014MN01839A (de) 2012-02-28 2013-02-27

Country Status (16)

Country Link
US (1) US20150072969A1 (de)
EP (1) EP2820005A1 (de)
JP (1) JP2015508809A (de)
KR (1) KR20140138243A (de)
CN (1) CN104144920A (de)
AR (1) AR090191A1 (de)
AU (1) AU2013227266A1 (de)
CA (1) CA2866210A1 (de)
IL (1) IL234254A (de)
IN (1) IN2014MN01839A (de)
MX (1) MX2014010272A (de)
NZ (1) NZ631569A (de)
RU (1) RU2014138894A (de)
TW (1) TW201341356A (de)
WO (1) WO2013128378A1 (de)
ZA (1) ZA201407034B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20142083A1 (es) 2011-09-16 2014-12-30 Fovea Pharmaceuticals Derivados de anilina, su preparacion y su aplicacion terapeutica
WO2015028960A1 (en) * 2013-08-28 2015-03-05 Piramal Enterprises Limited Substituted heterocyclic derivatives as gpr agonists and uses thereof
HK1221465A1 (zh) 2013-11-14 2017-06-02 Cadila Healthcare Limited 新型杂环化合物
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2015125085A1 (en) 2014-02-19 2015-08-27 Piramal Enterprises Limited Compounds for use as gpr120 agonists
US10273230B2 (en) 2014-07-25 2019-04-30 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
EP3177287B1 (de) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetische bicyclische verbindungen
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177285B1 (de) 2014-08-08 2020-09-23 Merck Sharp & Dohme Corp. [5,6]-kondensierte bicyclische antidiabetische verbindungen
WO2016032120A1 (ko) * 2014-08-27 2016-03-03 씨제이헬스케어 주식회사 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
KR101641023B1 (ko) 2014-08-27 2016-07-20 씨제이헬스케어 주식회사 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
CA2960757C (en) 2014-09-11 2022-09-06 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
KR102705659B1 (ko) 2018-01-08 2024-09-11 셀론 파르마 에스.에이. Gpr40 작용제로서 3-페닐-4-헥신산 유도체
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
EP4153589A4 (de) 2020-05-19 2024-06-12 Kallyope, Inc. Ampk-aktivatoren
EP4172162A4 (de) 2020-06-26 2024-08-07 Kallyope, Inc. Ampk-aktivatoren
WO2024211164A2 (en) * 2023-04-03 2024-10-10 Trustees Of Dartmouth College Fatty acid mimetics as modulators of gpr40 and/or gpr120

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
JP3400392B2 (ja) * 1994-10-18 2003-04-28 ファイザー製薬株式会社 5−リポキシゲナーゼ阻害剤及び新規医薬組成物
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
WO2001044223A1 (en) * 1999-12-17 2001-06-21 Abbott Laboratories Inhibitors of interleukin 5 gene expression
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
AU2003261319A1 (en) * 2002-08-01 2004-02-23 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
EP1690538A4 (de) * 2003-12-02 2009-02-25 Shionogi & Co Isoxazol-derivat mit agonistischer wirkung gegen peroxisom-proliferator-aktivierten rezeptor
KR20070004769A (ko) * 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
AU2006311524A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as PPAR modulators
WO2007137008A2 (en) * 2006-05-18 2007-11-29 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
BRPI0713378A8 (pt) 2006-06-27 2018-01-02 Takeda Pharmaceutical composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
US8030354B2 (en) * 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
KR20100135711A (ko) * 2007-12-20 2010-12-27 엔비보 파마슈티칼즈, 인코퍼레이티드 사중치환된 벤젠
AU2009220163B2 (en) 2008-03-06 2011-10-06 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
JP5551707B2 (ja) 2008-10-15 2014-07-16 アムジエン・インコーポレーテツド スピロ環gpr40調節因子
WO2010048207A2 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
PT2356113E (pt) * 2008-11-14 2015-04-14 Bayer Ip Gmbh Compostos arilo substituídos heterociclicamente como inibidores de hif
WO2010123016A1 (ja) 2009-04-22 2010-10-28 アステラス製薬株式会社 カルボン酸化合物
WO2010138901A1 (en) * 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
US20110015182A1 (en) * 2009-07-17 2011-01-20 Richard Franklin Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
DE102009046115A1 (de) * 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
NZ606827A (en) 2010-07-23 2015-02-27 Connexios Life Sciences Pvt Ltd Agonists of gpr40
EP2651930B1 (de) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamidhemmer der leukotrienproduktion

Also Published As

Publication number Publication date
US20150072969A1 (en) 2015-03-12
RU2014138894A (ru) 2016-04-20
IL234254A (en) 2017-03-30
TW201341356A (zh) 2013-10-16
WO2013128378A1 (en) 2013-09-06
ZA201407034B (en) 2017-08-30
KR20140138243A (ko) 2014-12-03
AR090191A1 (es) 2014-10-29
CA2866210A1 (en) 2013-09-06
NZ631569A (en) 2016-10-28
MX2014010272A (es) 2015-08-14
AU2013227266A1 (en) 2014-10-02
EP2820005A1 (de) 2015-01-07
JP2015508809A (ja) 2015-03-23
CN104144920A (zh) 2014-11-12

Similar Documents

Publication Publication Date Title
IN2014MN01839A (de)
JO3781B1 (ar) مشتقات الكينولون
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
PH12014502524B1 (en) Carboxylic acid compounds
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
IN2014MN00697A (de)
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
WO2014170842A3 (en) Substituted alkyl carboxylic acid derivatives as gpr agonists
EA201792072A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
IN2013DN02555A (de)
PH12013500671A1 (en) Novel gpr 119 agonists
IN2014KN01113A (de)
IN2013MN00581A (de)
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
MY168750A (en) Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists
MX2009013240A (es) Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.
TN2010000318A1 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production
TH149194A (th) องค์ประกอบทางเภสัชกรรมของสารประกอบสไปโร-ออกซินโดล สำหรับการให้ยาเฉพาะที่และการใช้สารนั้นเป็นสารบำบัดรักษา